Efficacy of Biologic Therapy in Moderate-to-Severe Psoriasis
Biologic therapy demonstrated 89% reduction in PASI score at week 16 compared to 12% with placebo. Quality of life improved...
Company: Johnson & Johnson
Johnson & Johnson – Pharmaceutical division
Early Intervention in Vitiligo: Outcomes and Predictors
Early treatment within 6 months of onset achieved 75% repigmentation vs 28% for delayed treatment. Facial lesions responded best.
Rosacea Subtype-Specific Treatment Approaches
Tailored therapy based on rosacea subtype achieved 72% improvement vs 43% with standard approach. Combination therapy most effective.